@article{uoadl:3485235,
    volume = "35",
    pages = "37 – 44",
    journal = "Mediterranean Journal of Rheumatology",
    keywords = "bardoxolone methyl; baricitinib; cep 33779; deucravacitinib; double stranded DNA antibody; elsubrutinib; filgotinib; glucocorticoid; Janus kinase; Janus kinase 1; Janus kinase 2; Janus kinase inhibitor; placebo; ruxolitinib; s31 201; solcitinib; STAT1 protein; STAT3 protein; STAT4 protein; stattic; suppressor of cytokine signaling 1; tofacitinib; tumor necrosis factor inhibitor; unclassified drug; upadacitinib; alopecia areata; ankylosing spondylitis; Article; atopic dermatitis; autoimmune disease; cardiovascular disease; cerebrovascular accident; discoid lupus erythematosus; DRESS syndrome; drug dose comparison; drug efficacy; drug safety; drug targeting; heart infarction; herpes zoster; human; hypertransaminasemia; infection; JAK-STAT signaling; lupus erythematosus nephritis; monotherapy; myelofibrosis; non melanoma skin cancer; nonhuman; opportunistic infection; pathophysiology; proteinuria; psoriasis vulgaris; psoriatic arthritis; remission; rheumatoid arthritis; skin lupus erythematosus; systemic lupus erythematosus; thromboembolism; tuberculosis; ulcerative colitis; venous thromboembolism",
    BIBTEX_ENTRY = "article",
    year = "2024",
    author = "Moysidou, Georgia-Savina and Dara, Athanasia",
    abstract = "Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules responsible for signal transduction of multiple cytokines and growth factors in different cell types, involved in the maintenance of immune tolerance. Thus, the dysregulation of this pathway plays a crucial role in the pathogenesis of multiple autoimmune, inflammatory, and allergic diseases and is an attractive treatment target. JAK inhibitors (JAKinibs) have been approved in the treatment of multiple autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (SPA). In SLE, there is a plethora of ongoing trials evaluating their efficacy, with tofacitinib, baricitinib and deucravacitinib showing promising results, without major safety concerns. In this review, we will discuss the rationale of targeting JAKinibs in SLE and summarize the clinical data of efficacy and safety of JAKinibs in SLE patients. © (2024), The Author(s).",
    title = "JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus",
    doi = "10.31138/MJR.231123.JIA"
}